Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $263,685 | 159 | 87.0% |
| Travel and Lodging | $15,224 | 119 | 5.0% |
| Food and Beverage | $15,016 | 689 | 5.0% |
| Consulting Fee | $8,994 | 6 | 3.0% |
| Education | $289.60 | 14 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $106,105 | 350 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $62,678 | 128 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $56,597 | 130 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $34,075 | 81 | $0 (2020) |
| Lilly USA, LLC | $21,359 | 67 | $0 (2024) |
| Amgen Inc. | $15,993 | 73 | $0 (2022) |
| Corcept Therapeutics | $3,732 | 19 | $0 (2019) |
| Medtronic MiniMed, Inc. | $287.36 | 4 | $0 (2019) |
| Insulet Corporation | $284.28 | 4 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $212.96 | 21 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $250.56 | 18 | Novo Nordisk Inc ($167.31) |
| 2023 | $2,771 | 54 | Novo Nordisk Inc ($2,314) |
| 2022 | $21,290 | 73 | Novo Nordisk Inc ($18,486) |
| 2021 | $34,766 | 94 | Novo Nordisk Inc ($15,028) |
| 2020 | $37,766 | 123 | Novo Nordisk Inc ($17,164) |
| 2019 | $80,947 | 223 | SANOFI-AVENTIS U.S. LLC ($22,023) |
| 2018 | $82,632 | 220 | Novo Nordisk Inc ($32,273) |
| 2017 | $42,785 | 182 | AstraZeneca Pharmaceuticals LP ($15,012) |
All Payment Transactions
987 individual payment records from CMS Open Payments — Page 1 of 40
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.89 | General |
| Category: Diabetes | ||||||
| 10/18/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $9.55 | General |
| Category: Diabetes | ||||||
| 10/17/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $12.66 | General |
| Category: Diabetes | ||||||
| 07/24/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: Diabetes | ||||||
| 06/07/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: Diabetes | ||||||
| 06/06/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.92 | General |
| Category: Diabetes | ||||||
| 05/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Education | In-kind items and services | $13.76 | General |
| Category: INTERNAL MEDICINE | ||||||
| 05/07/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $11.56 | General |
| Category: Diabetes | ||||||
| 04/26/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $12.02 | General |
| Category: Diabetes | ||||||
| 04/17/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.43 | General |
| Category: Cardio-renal | ||||||
| 04/09/2024 | IBSA Pharma Inc. | Tirosint (Drug), Licart | Food and Beverage | Cash or cash equivalent | $16.75 | General |
| Category: Endocrinology | ||||||
| 04/03/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $6.20 | General |
| Category: Diabetes | ||||||
| 04/02/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $9.76 | General |
| Category: Diabetes | ||||||
| 03/14/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: Diabetes | ||||||
| 02/21/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $10.48 | General |
| Category: Diabetes | ||||||
| 02/15/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $11.29 | General |
| Category: Diabetes | ||||||
| 01/24/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: Diabetes | ||||||
| 01/24/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: PAIN MANAGEMENT | ||||||
| 12/07/2023 | Tolmar, Inc. | JATENZO (Drug) | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: Endogenous Testosterone Replacement Therapy | ||||||
| 11/28/2023 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $7.78 | General |
| Category: PAIN MANAGEMENT | ||||||
| 11/22/2023 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $23.19 | General |
| Category: Diabetes Care | ||||||
| 10/30/2023 | SANOFI-AVENTIS U.S. LLC | TOUJEO (Biological) | Food and Beverage | In-kind items and services | $24.22 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 10/25/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: Diabetes | ||||||
| 10/25/2023 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $8.84 | General |
| Category: PAIN MANAGEMENT | ||||||
| 10/20/2023 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $17.92 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 228 | 309 | $29,839 | $17,532 |
| 2022 | 4 | 229 | 312 | $30,634 | $17,366 |
| 2021 | 4 | 244 | 323 | $36,690 | $17,925 |
| 2020 | 9 | 509 | 1,293 | $71,836 | $34,653 |
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 103 | 158 | $16,676 | $10,621 | 63.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 35 | 48 | $7,382 | $4,787 | 64.8% |
| 76536 | Ultrasound scan of head and neck soft tissue | Facility | 2023 | 75 | 80 | $4,240 | $1,541 | 36.4% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 15 | 23 | $1,541 | $583.44 | 37.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 121 | 182 | $20,573 | $12,341 | 60.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 17 | 25 | $4,106 | $2,657 | 64.7% |
| 76536 | Ultrasound scan of head and neck soft tissue | Facility | 2022 | 76 | 79 | $4,187 | $1,649 | 39.4% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 15 | 26 | $1,768 | $718.96 | 40.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 129 | 182 | $24,470 | $12,175 | 49.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 25 | 33 | $6,061 | $3,417 | 56.4% |
| 76536 | Ultrasound of head and neck | Facility | 2021 | 73 | 79 | $4,187 | $1,599 | 38.2% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 17 | 29 | $1,972 | $734.48 | 37.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 13 | 780 | $17,160 | $11,665 | 68.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 109 | 114 | $16,644 | $6,810 | 40.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 86 | 89 | $12,994 | $5,250 | 40.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 37 | 38 | $4,554 | $2,472 | 54.3% |
| 76536 | Ultrasound of head and neck | Facility | 2020 | 101 | 105 | $5,565 | $2,302 | 41.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 22 | 22 | $4,312 | $1,727 | 40.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 16 | 18 | $3,528 | $1,619 | 45.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 24 | 24 | $3,504 | $1,475 | 42.1% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Facility | 2020 | 17 | 19 | $1,369 | $524.32 | 38.3% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2020 | 13 | 13 | $968.00 | $287.29 | 29.7% |
| 83036 | Hemoglobin a1c level | Office | 2020 | 29 | 29 | $667.00 | $276.08 | 41.4% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 16 | 16 | $467.00 | $164.77 | 35.3% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2020 | 26 | 26 | $104.00 | $80.91 | 77.8% |
About Kara Hoisington
Kara Hoisington is a Internal Medicine healthcare provider based in Lansing, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/07/2007. The National Provider Identifier (NPI) number assigned to this provider is 1588877419.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Kara Hoisington has received a total of $303,208 in payments from pharmaceutical and medical device companies, with $250.56 received in 2024. These payments were reported across 987 transactions from 42 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($263,685).
As a Medicare-enrolled provider, Hoisington has provided services to 1,210 Medicare beneficiaries, totaling 2,237 services with total Medicare billing of $87,477. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Diabetes & Metabolism
- Location Lansing, MI
- Active Since 05/07/2007
- Last Updated 05/04/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1588877419
Products in Payments
- JARDIANCE (Drug) $54,830
- Ozempic (Drug) $43,595
- FARXIGA (Drug) $43,026
- TOUJEO (Drug) $23,103
- RYBELSUS (Drug) $18,946
- SOLIQUA (Drug) $17,838
- Prolia (Biological) $15,752
- BYDUREON (Drug) $13,463
- Rybelsus (Drug) $9,766
- Tresiba (Drug) $9,290
- SOLIQUA 100/33 (Drug) $8,237
- Victoza (Drug) $7,450
- SOLIQUA 100/33 (Biological) $7,058
- TOUJEO (Biological) $6,420
- Korlym (Drug) $3,732
- Omnipod (Device) $284.28
- Saxenda (Drug) $213.11
- JANUVIA (Drug) $212.96
- Qutenza (Drug) $193.62
- V-GO (Device) $188.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Lansing
Dr. Peter Gulick, D.o, D.O
Internal Medicine — Payments: $1.1M
Dr. Joshua June, Do, DO
Internal Medicine — Payments: $456,912
Chris Farnum, Do, DO
Internal Medicine — Payments: $117,503
Miki Yokokawa, Md, MD
Internal Medicine — Payments: $84,271
Dr. Khader Herzallah, Md, MD
Internal Medicine — Payments: $48,157
Dr. Mohammad Kanjwal, Md, MD
Internal Medicine — Payments: $45,493